When prescribed in an internal medicine setting, this medication serves a dual purpose: treating obesity while simultaneously correcting metabolic dysfunction, thereby offering a comprehensive approach to preventing future chronic disease
Until recently, the published studies with the new obesity pharmacotherapies have had up to 2 years follow-up [12]
Long-Acting strategies for GLP-1 RAs, source: Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP, Drug Design, Development and Therapy, Oral Formulation The only available oral GLP-1RA is semaglutide (Rybelsus, Novo Nordisk)
Chest pain that mimics a heart attack Ask the doctor Q
Quick tip: Steer clear of moles, scars, waistbands, or freshly shaved skin to reduce the chance of mild injection site reactions
Medical Eligibility Check: Determination if compounded semaglutide is suitable for you based on your goals and health history